RxDoctor Payments Data

Paul Snyder, MD

Dermatology · Dartmouth, MANPI 1477551398

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 90.5% of the total across 230 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 21 manufacturers, the largest accounting for just 20.7% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,759, 3.4 times the $520 reported in 2019.

$4,901in general payments, 2019–2025

Across 230 payments — averaging $21.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • LEO Pharma Inc.$830
  • Johnson & Johnson$760
  • Novartis$416
  • Regeneron Healthcare Solutions, Inc.$383
  • Incyte Corporation$231
  • plus $1K from 15 others

What the payments were for

  • Food & beverage$4,43691%
  • Education$4659%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$4,901 in reported general payments places this provider in the 70th percentile of 552 dermatology providers in Massachusetts.

See all dermatology providers in Massachusetts →

Medicare billing

Part B allowed, 2024
$341,722
Medicare patients
668
Services billed
4,262

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Enbrel SureclickEtanercept23$245,195
Dupixent PenDupilumab41$159,868
Humira(Cf) PenAdalimumab15$99,482
Cosentyx Sensoready (2 Pens)Secukinumab13$96,367
Fluorouracil40$2,788
Betamethasone Dipropionate42$1,628
Tretinoin12$1,374
Dapsone13$1,259
Imiquimod27$1,103
Metronidazole16$1,005
Mupirocin155$966
Triamcinolone Acetonide57$756
Doxycycline Hyclate30$663
Fluocinonide12$655
CiclopiroxCiclopirox Olamine28$616

Paid to pharmacies, not to this prescriber.

Other dermatology in Dartmouth

See the full list for Massachusetts →

Where these figures come from

Is this you, or does something look wrong? →